Combination 'epigenetic' therapy may restore anti-cancer gene activity in late-stage lung cancer patients

A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial. Forty-five late-stage lung cancer patients who received a two-drug combination designed to restore anti-cancer gene activity survived about two months longer than the expected four months, and two patients showed complete or near-complete responses despite having progressive disease after multiple standard therapies.

Read the whole article on Science Daily

More from Science Daily